Showing 2 results for Ahmadi Vasmehjani
Azam Ahmadi Vasmehjani, Fatemeh Yaghoubi, Zahra Darabi, Nooshin Abdollahi, Zohreh Sadat Sangsefidi, Mahdieh Hosseinzadeh,
Volume 7, Issue 4 (NOV 2022)
Abstract
Background: Quercetin is one of the main flavonoids, overall distributed in plants. The antioxidant capacity of quercetin is several times vitamin E and glutathione. This systematic review and meta‐analysis of randomized controlled trials were performed to determine the effect of quercetin on oxidative stress (OS) markers. Methods: A literature search was conducted in PubMed, ISI Web of Science, Scopus, and Google Scholar to February of 2021. Meta-analysis was conducted on 8 eligible RCTs containing a total of 668 participants. The weighted mean difference (WMD) with 95% confidence intervals (CIs) was calculated for a pool effect size of Malondialdehyde (MDA), Total Antioxidant Capacity (TAC), and Ferric Reducing Ability of Plasma (FRAP). Subgroup analyses were performed based on intervention duration and dosage. The heterogeneity of studies was examined by Cochran's Q test and I-squared (I2) statistic. Results: Effect sizes from 668 participants based on the random effect model showed that quercetin supplementation had no significant effect on TAC and MDA compared to the control group. The analysis illustrated that quercetin supplementation significantly increased FRAP in adults (WMD = -0.159 mmol/l, 95% confidence interval (CI):-0.178, -0.141, P ≤ 0.001). Conclusions: The finding of the current study showed that quercetin supplementation had no significant effect on TAC levels, although it significantly increased FRAP levels in adults. Also, MDA level did not markedly change. It has needed to conduct clinical trials with more quality and bigger sample sizes to verify the positive impact of quercetin on stress oxidative marker.
Fatemeh Yaghoubi, Zahra Darabi, Azam Ahmadi Vasmehjani, Zohreh Sadat Sangsefidi, Mahdieh Hosseinzadeh,
Volume 7, Issue 4 (NOV 2022)
Abstract
Background: This systematic review and meta‐analysis of randomized controlled trials (RCTs) was conducted to determine the effect of dark chocolate on C-Reactive Protein (CRP) levels as one of the inflammatory factors. Methods: A literature search was conducted in PubMed, ISI Web of Science, Scopus, and Google Scholar up to April of 2020. The registration number of study in PROSPERO was CRD4202020072, which was conducted over 5 eligible RCTs containing a total of 330 participants. The weighted mean difference (WMD) with 95% confidence intervals was calculated for the pool effect size of CRP. The heterogeneity of studies was examined by Cochran's Q test and I-squared (I2) statistic. Results: Effect sizes from 330 participants based on random effect model showed no effect between consumption of dark chocolate on CRP levels compared to the control group (WMD: 0.01 mg/dl; 95% CI: −0.19, 0.22 mg/dl; P = 0.89; Cochran's Q test, Q statistic = 21.97; P < 0.001; I2 = 81.80%). The results of subgroup analysis based on intervention duration and dosage showed no significant effect on CRP levels (WMD = 0.05 mg/dl, 95% CI: −0.30, 0.42 mg/dl; P = 0.76). Meta-regression for the intervention duration (slope: −0.0033, 95% CI: −0.0089, 0.0022; P = 0.24) and dosage (slope: 0.00006, 95% CI: −0.0036, 0.0037; P = 0.97) indicated no significant relationship with the mean difference of CRP. Conclusion: The results of the present meta-analysis showed that consuming dark chocolate had no significant effect on the CRP level. More clinical trials are required with higher quality and bigger sample sizes to verify the positive impact of dark chocolate on the reduction CRP level.
